Oncocyte Corporation (OCX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Oncocyte Corporation (OCX:NASDAQ), powered by AI.

Current Price
$3.76
P/E Ratio
-0.8
Market Cap
49M
Sector
Healthcare
What is the Oncocyte Corporation stock price forecast?

Oncocyte Corporation is currently trading at $3.76. View real-time AI analysis on Alpha Lenz.

What is Oncocyte Corporation insider trading activity?

View the latest insider trading data for Oncocyte Corporation on Alpha Lenz.

What is Oncocyte Corporation's P/E ratio?

Oncocyte Corporation's P/E ratio is -0.8.

Oncocyte Corporation

$3.76
NASDAQOCX
Ask about Oncocyte Corporation's future dividend policy...
Alpha Chat Insight

Oncocyte Corporation trades at a P/E of -0.8 (undervalued) with modest ROE of -1480.7%.

Ask for details

Company Overview

Oncocyte Corporation is a biotechnology company focused on the development of molecular diagnostic tests for the detection of cancer. The primary function of Oncocyte is to improve patient outcomes by enhancing cancer diagnosis and monitoring through advanced genomic testing technologies. Its tests are designed to empower physicians with precise information, enabling more informed decisions regarding cancer treatment and management. Operating in the healthcare sector, Oncocyte plays a vital role in the fields of oncology and precision medicine, as it works towards personalized treatment options. The company’s mission is also to address the limitations of existing diagnostic methods by providing more accurate and less invasive alternatives. With a commitment to research and innovation, Oncocyte's offerings have the potential to significantly impact the early detection and treatment efficacy of various cancers. By focusing on unmet needs in the cancer diagnosis landscape, Oncocyte Corporation contributes to the broader healthcare market in efforts to improve patient care and clinical outcomes.

CEOMr. Joshua Riggs
SectorHealthcare
IndustryDiagnostics & Research
Employees46

Company Statistics

(FY 2024)

Profile

Market Cap$49.15M
Revenue$1.88M
Shares Out0.00
Employees46

Margins

Gross39.34%
EBITDA-1128.18%
Operating-1235.89%
Pre-Tax-3225.04%
Net-3225.04%

Valuation

P/E-0.81
P/B-4.00
EV/Sales26.13
EV/EBITDA-2.08
P/FCF-2.32

Growth (CAGR)

Rev 3Yr-5.06%
Rev 5YrN/A
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-110.32%
ROE-1480.67%
ROIC-110.17%

Financial Health

Cash & Cash Equivalents$8.64M
Net Debt$38.72M
Debt/Equity-385.82%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Oncocyte Corporation (Healthcare) Stock Forecast & Analysis $3.76 | Alpha Lenz